The new results showed that MDV3100 continues to show durable antitumor activity as evaluated by median times to prostate-specific antigen (PSA) progression and radiographic progression.
These findings confirm the initial Phase 1-2 results, in which MDV3100 consistently demonstrated anti-tumor activity in both chemotherapy-naïve and post-chemotherapy patients across endpoints, as evaluated by PSA levels, radiographic findings and circulating tumor cell (CTC) counts.
In October 2009, Medivation and Astellas entered into a global agreement to jointly develop and commercialize MDV3100 for both early-stage and advanced prostate cancer.
Subject to receipt of regulatory approval, the companies will jointly commercialize MDV3100 in the US and Astellas will have responsibility for commercializing MDV3100 outside the US.
Medivation received a $110m up-front payment upon entering into the collaboration agreement.
It is eligible to receive up to $335m in development milestone payments, up to $320m in commercial milestone payments, 50% of profits on sales in the US, and tiered, double-digit royalties on sales outside the US.